Thermo Fisher Scientific said on Tuesday that it has received CE-IVD marking for its Oncomine Dx Express Test, a next-generation sequencing tumor mutation profiling test, and the companion Oncomine Reporter Dx analysis software and has launched them.

Genomenon said Tuesday that it has been named the exclusive gene curation partner for Rady Children's Institute for Genomic Medicine's (RCIGM) recently launched BeginNGS newborn screening panel.

The National Comprehensive Cancer Network on Tuesday published new guidelines for treating children with brain cancer, underscoring the importance of broad molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for patients.

Illumina and Beckman Coulter Life Sciences said on Tuesday that they have partnered on application development for the Biomek NGenius next-generation library preparation system.

Beckman Coulter Life Sciences announced on Monday that it has inked an application development agreement with Integrated DNA Technologies for its forthcoming Biomek NGenius next-generation library preparation system.

Beckman Coulter Life Sciences said on Monday that it has entered into an agreement with Invitae to develop applications for Beckman's new next-generation sequencing library preparation system.

On August 5, 2021, Pillar Biosciences announced the FDA has given PMA to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors

Qiagen and OncXerna Therapeutics said on Monday that they have signed a master agreement to develop a next-generation sequencing companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.

On July 6, 2021, Agilent Technologies (NYSE: A) announced a strategic collaboration with GenomiCare Biotechnology in a move aimed to advance the application of the latest Next Generation Sequencing (NGS) technology into the clinical and scientific arena.

On Aug 7th, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology.